Immunoaffinity Mass Spectrometry Diagnostic Tests for Multi-Biomarker Assays

Area of Science:

• Biochemistry
• Analytical Chemistry
• Clinical Diagnostics

Background:

• Diabetic kidney disease (DKD) requires accurate prognostic biomarkers.
• Immunoaffinity mass spectrometry (MS) offers high selectivity and analytical performance for biomarker assays.
• Current methods may lack the throughput and robustness for widespread clinical use.

Purpose of the Study:

• To develop and validate a novel immunoaffinity mass spectrometry method for quantifying three protein biomarkers relevant to DKD prognosis.
• To establish a high-throughput and clinically applicable assay for DKD biomarker detection.
• To enable rapid and accurate assessment of DKD progression.

Main Methods:

• Preparation and purification of antibody-bead conjugates for three target proteins.
• On-bead immunoaffinity capture followed by reduction, alkylation, and digestion.
• Targeted microflow liquid chromatography-tandem mass spectrometry (LC-MS/MS) for quantification.

Main Results:

• Successful development of an immunoaffinity MS assay for three DKD prognostic biomarkers.
• Demonstration of a robust workflow compatible with clinical settings.
• Achieved rapid quantification of biomarkers within an 8-minute run time.

Conclusions:

• The developed immunoaffinity MS method provides a sensitive, specific, and rapid approach for DKD biomarker quantification.
• This methodology holds significant potential for improving prognostic accuracy and guiding clinical management of diabetic kidney disease.
• The assay's compatibility with higher throughput and clinical application makes it a valuable tool for diagnostic biomarker assays.